<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324255</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0031</org_study_id>
    <nct_id>NCT04324255</nct_id>
  </id_info>
  <brief_title>Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant</brief_title>
  <official_title>Von Willebrand Factor and Protein c Ratio-related Thrombogenicity With Systemic Inflammation is Predictive of Graft Dysfunction After Liver Transplantation: Retrospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13
      is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been
      reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and
      persists even after LT. Such changes are thought to contribute to postoperative thrombotic
      complications, which may lead to early adverse events of thrombotic microangiopathy after
      living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure
      following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and
      anticoagulant, such as PC.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early allograft dysfunction</measure>
    <time_frame>within 7 days after surgery</time_frame>
    <description>Immediate liver graft function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft failure</measure>
    <time_frame>90 days</time_frame>
    <description>re-liver transplantation or death, whichever was first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intensive care unit stay</measure>
    <time_frame>until the day of patients moving to general wards, through study completion, an average of 1 year</time_frame>
    <description>days of intensive care unit stay after liver transplant</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1199</enrollment>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Low ratio</arm_group_label>
    <description>Liver recipient with low preoperative von Willbrand factor-to-protein C ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High ratio</arm_group_label>
    <description>Liver recipient with high preoperative von Willbrand factor-to-protein C ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LT</intervention_name>
    <description>Liver transplantation</description>
    <arm_group_label>High ratio</arm_group_label>
    <arm_group_label>Low ratio</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        End-stage liver disease patients undergoing liver transplant
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients who underwent LT

        Exclusion Criteria:

        deceased-donor liver transplant, and insufficient data, ABO-incompatible LT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Hyemee Kwon</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The release of data is not within my permission.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

